Elizabeth A Bye1,2,3, Martin E Héroux1,3, Claire L Boswell-Ruys1,2,3, Monica A Perez4, Mariel Purcell5, Julian Taylor6,7, Bonsan B Lee1,2,3, Euan J McCaughey1,3,5, Jane E Butler1,3, Simon C Gandevia8,9. 1. Neuroscience Research Australia, Randwick, NSW, 2031, Australia. 2. Prince of Wales Hospital, Randwick, NSW, 2031, Australia. 3. School of Medical Sciences, University of New South Wales, Kensington, NSW, 2052, Australia. 4. Shirley Ryan Ability Lab, Northwestern University, Hine VA Hospital, Chicago, USA. 5. Queen Elizabeth National Spinal Injuries Unit, Queen Elizabeth University Hospital, Glasgow, G51 4TF, Scotland. 6. Hospital Nacional de Parapléjicos, SESCAM, Toledo, 45071, Spain. 7. Harris Manchester College, University of Oxford, Oxford, OX1 3TD, UK. 8. Neuroscience Research Australia, Randwick, NSW, 2031, Australia. s.gandevia@neura.edu.au. 9. School of Medical Sciences, University of New South Wales, Kensington, NSW, 2052, Australia. s.gandevia@neura.edu.au.
Abstract
STUDY DESIGN: An international multi-centred, double-blinded, randomised sham-controlled trial (eWALK). OBJECTIVE: To determine the effect of 12 weeks of transcutaneous spinal stimulation (TSS) combined with locomotor training on walking ability in people with spinal cord injury (SCI). SETTING: Dedicated SCI research centres in Australia, Spain, USA and Scotland. METHODS: Fifty community-dwelling individuals with chronic SCI will be recruited. Participants will be eligible if they have bilateral motor levels between T1 and T11, a reproducible lower limb muscle contraction in at least one muscle group, and a Walking Index for SCI II (WISCI II) between 1 and 6. Eligible participants will be randomised to one of two groups, either the active stimulation group or the sham stimulation group. Participants allocated to the stimulation group will receive TSS combined with locomotor training for three 30-min sessions a week for 12 weeks. The locomotor sessions will include walking on a treadmill and overground. Participants allocated to the sham stimulation group will receive the same locomotor training combined with sham stimulation. The primary outcome will be walking ability with stimulation using the WISCI II. Secondary outcomes will record sensation, strength, spasticity, bowel function and quality of life. TRIAL REGISTRATION: ANZCTR.org.au identifier ACTRN12620001241921.
STUDY DESIGN: An international multi-centred, double-blinded, randomised sham-controlled trial (eWALK). OBJECTIVE: To determine the effect of 12 weeks of transcutaneous spinal stimulation (TSS) combined with locomotor training on walking ability in people with spinal cord injury (SCI). SETTING: Dedicated SCI research centres in Australia, Spain, USA and Scotland. METHODS: Fifty community-dwelling individuals with chronic SCI will be recruited. Participants will be eligible if they have bilateral motor levels between T1 and T11, a reproducible lower limb muscle contraction in at least one muscle group, and a Walking Index for SCI II (WISCI II) between 1 and 6. Eligible participants will be randomised to one of two groups, either the active stimulation group or the sham stimulation group. Participants allocated to the stimulation group will receive TSS combined with locomotor training for three 30-min sessions a week for 12 weeks. The locomotor sessions will include walking on a treadmill and overground. Participants allocated to the sham stimulation group will receive the same locomotor training combined with sham stimulation. The primary outcome will be walking ability with stimulation using the WISCI II. Secondary outcomes will record sensation, strength, spasticity, bowel function and quality of life. TRIAL REGISTRATION: ANZCTR.org.au identifier ACTRN12620001241921.
Authors: Susan Harkema; Yury Gerasimenko; Jonathan Hodes; Joel Burdick; Claudia Angeli; Yangsheng Chen; Christie Ferreira; Andrea Willhite; Enrico Rejc; Robert G Grossman; V Reggie Edgerton Journal: Lancet Date: 2011-05-19 Impact factor: 79.321
Authors: Megan L Gill; Peter J Grahn; Jonathan S Calvert; Margaux B Linde; Igor A Lavrov; Jeffrey A Strommen; Lisa A Beck; Dimitry G Sayenko; Meegan G Van Straaten; Dina I Drubach; Daniel D Veith; Andrew R Thoreson; Cesar Lopez; Yury P Gerasimenko; V Reggie Edgerton; Kendall H Lee; Kristin D Zhao Journal: Nat Med Date: 2018-09-24 Impact factor: 53.440
Authors: Monzurul Alam; Yan To Ling; Arnold Y L Wong; Hui Zhong; Victor Reggie Edgerton; Yong-Ping Zheng Journal: Ann Clin Transl Neurol Date: 2020-05-20 Impact factor: 4.511